1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 18
2.1 Market Size and Forecast 18
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 31
2.4 Emerging Opportunities and Market Trends 34
2.5 Porters Fiver Forces Analysis 38
3 Segmentation of North America Market by Product Type 42
3.1 Market Overview by Product Type 42
3.2 Recombinant Non-glycosylated Biosimilars 44
3.2.1 Insulin 46
3.2.2 Recombinant Human Growth Hormone (rHGH) 47
3.2.3 Granulocyte Colony Stimulating Factor 48
3.2.4 Interferon 49
3.3 Recombinant Glycosylated Biosimilars 50
3.3.1 Monoclonal Antibodies (mAb) 51
3.3.2 Erythropoietin (EPO) 52
3.3.3 Follicle Stimulating Hormone 53
3.4 Recombinant Peptides and Others 54
3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 55
3.4.2 Parathyroid Hormone 56
3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 57
4 Segmentation of North America Market by Indication 58
4.1 Market Overview by Indication 58
4.2 Cancer 60
4.3 Autoimmune Disease 61
4.4 Blood Disorder 62
4.5 Diabetes 63
4.6 Growth Hormone Deficiency 64
4.7 Infectious Diseases 65
4.8 Other Indications 66
5 Segmentation of North America Market by Manufacturing 67
5.1 Market Overview by Manufacturing 67
5.2 Contract Manufacturing 69
5.3 Inhouse Manufacturing 70
6 Segmentation of North America Market by End User 71
6.1 Market Overview by End User 71
6.2 Hospitals and Clinics 73
6.3 Research Institutes 74
6.4 Other End Users 75
7 North America Market 2019-2030 by Country 76
7.1 Overview of North America Market 76
7.2 U.S. 79
7.3 Canada 89
7.4 Mexico 91
8 Competitive Landscape 93
8.1 Overview of Key Vendors 93
8.2 New Product Launch, Partnership, Investment, and M&A 97
8.3 Company Profiles 98
AMEGA Biotech S.A. 98
Apotex Inc. 100
Biocon Ltd 101
Biogen Inc. 102
Boehringer Ingelheim 103
Celltrion, Inc. 104
Dr. Reddys Laboratories Ltd. 105
Eli Lilly and Company 106
Intas Pharmaceuticals Ltd. 107
LG Chem, Ltd. 108
Merck and Co. Inc. 109
Mylan N.V. 110
Pfizer Inc. 111
Samsung Biologics Co., Ltd. 112
Sandoz International GmbH 113
STADA Arzneimittel AG 114
Teva Pharmaceutical Industries Ltd. 115
RELATED REPORTS 116